author-photo

Brenda J. Weigel

University of Minnesota

34

Papers

224

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

Toxicity and pharmacokinetics of actinomycin-D and vincristine in children and adolescents: Children's Oncology Group Study ADVL06B1.

2021 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (1)
Outcome of patients with recurrent/refractory osteosarcoma enrolled in three recent phase II trials: A report from the Children’s Oncology Group.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Strategies for New Agent Development in Pediatric Sarcomas

2021
- Emily G Greengard
- Brenda J. Weigel
Show All
- Source
- Cite
- Save
Citations (0)
Activity of Crizotinib in Patients with ALK-aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912).

2021 Clinical Cancer Research
Show All
- Source
- Cite
- Save
Citations (14)
Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1 study of prexasertib (LY2606368), a CHK1/2 inhibitor, in pediatric patients with recurrent or refractory solid tumors, including CNS tumors: A report from the Children's Oncology Group Pediatric Early Phase Clinical Trials Network (ADVL1515).

2021 Pediatric Blood & Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A phase 1 study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN).

2021 Pediatric Blood & Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)